Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 5;16(1):99.
doi: 10.1186/s12968-014-0099-4.

Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance

Affiliations

Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance

Silvia Pica et al. J Cardiovasc Magn Reson. .

Abstract

Background: Cardiovascular magnetic resonance (CMR) derived native myocardial T1 is decreased in patients with Fabry disease even before left ventricular hypertrophy (LVH) occurs and may be the first non-invasive measure of myocyte sphingolipid storage. The relationship of native T1 lowering prior to hypertrophy and other candidate early phenotype markers are unknown. Furthermore, the reproducibility of T1 mapping has never been assessed in Fabry disease.

Methods: Sixty-three patients, 34 (54%) female, mean age 48±15 years with confirmed (genotyped) Fabry disease underwent CMR, ECG and echocardiographic assessment. LVH was absent in 25 (40%) patients. Native T1 mapping was performed with both Modified Look-Locker Inversion recovery (MOLLI) sequences and a shortened version (ShMOLLI) at 1.5 Tesla. Twenty-one patients underwent a second scan within 24 hours to assess inter-study reproducibility. Results were compared with 63 healthy age and gender-matched volunteers.

Results: Mean native T1 in Fabry disease (LVH positive), (LVH negative) and healthy volunteers was 853±50 ms, 904±46 ms and 968±32 ms (for all p<0.0001) by ShMOLLI sequences. Native T1 showed high inter-study, intra-observer and inter-observer agreement with intra-class correlation coefficients (ICC) of 0.99, 0.98, 0.97 (ShMOLLI) and 0.98, 0.98, 0.98 (MOLLI). In Fabry disease LVH negative individuals, low native T1 was associated with reduced echocardiographic-based global longitudinal speckle tracking strain (-18±2% vs -22±2%, p=0.001) and early diastolic function impairment (E/E'=7 [6-8] vs 5 [5-6], p=0.028).

Conclusion: Native T1 mapping in Fabry disease is a reproducible technique. T1 reduction prior to the onset of LVH is associated with early diastolic and systolic changes measured by echocardiography.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Native T1 mapping in Fabry disease using ShMOLLI at 1.5 T. Top left: normal. Top right: a Fabry disease subject without LVH but clear myocardial T1 reduction – the myocardium is blue. Bottom left: Typical T1 when LVH present: the myocardial T1 is lower than without LVH and the basal infero-lateral wall has T1 elevation with a normal (pseudonormal?) surrounding area. Bottom right: rarely (4 patients), Fabry disease has a normal T1.
Figure 2
Figure 2
Mean septal T1 in LVH negative patients (n = 25), LVH positive patients (n = 38) and healthy volunteers (n = 63). Red solid line indicates -2SD below the mean native T1 of females healthy volunteers. Blue solid line indicates -2SD below the mean native T1 of males healthy volunteers.
Figure 3
Figure 3
Systolic and diastolic function in LVH negative Fabry disease patients. Global longitudinal speckle tracking strain of LVH negative-T1↓ subjects vs LVH negative-T1N subjects (left); E/E’ of LVH negative-T1↓ subjects vs LVH negative-T1N subjects (right).
Figure 4
Figure 4
Reproducibility of ShMOLLI sequences. ShMOLLI inter-study correlation (upper pannel) and Bland Altman analysis (lower pannel).

Similar articles

Cited by

References

    1. O’Mahony C, Elliott P. Anderson-fabry disease and the heart. ProgCardiovasc Dis. 2010;52(4):326–335. doi: 10.1016/j.pcad.2009.11.002. - DOI - PubMed
    1. Mehta A, Clarke JTR, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G. Natural course of fabry disease: changing pattern of causes of death in FOS – fabry outcome survey. J Med Genet. 2009;46(8):548–552. doi: 10.1136/jmg.2008.065904. - DOI - PubMed
    1. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB. Effects of enzyme replacement therapy on the cardiomyopathy of anderson-fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94(2):153–158. doi: 10.1136/hrt.2006.104026. - DOI - PubMed
    1. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance in anderson-fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 2003;24:2151–2155. doi: 10.1016/j.ehj.2003.09.017. - DOI - PubMed
    1. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of fabry disease in females in the fabry outcome survey. J Med Genet. 2006;43(4):347–352. doi: 10.1136/jmg.2005.036327. - DOI - PMC - PubMed

MeSH terms